Pharmacokinetic drug evaluation of albutrepenonacog alfa (CSL654) for the treatment of hemophilia

References

• Valentino LA, Rusen L, Elezovic I, et al. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia. 2014;20:398–406.
   PubMed Web of Science ®Google Scholar
• Blanchette VS, Manco-Johnson M, Santagostino E, et al. Optimizing factor prophylaxis for the haemophilia population: where do we stand?. Haemophilia. 2004;10(Suppl 4):97–104. Review.
   PubMed Web of Science ®Google Scholar
• Brand B, Dunn S, Kulkarni R. Challenges in the management of haemophilia on transition from adolescence to adulthood. Eur J Haematol. 2015;95(Suppl 81):30–35. Review.
   PubMed Web of Science ®Google Scholar
• Giangrande P. The future of hemophilia treatment: longer-acting factor concentrates versus gene therapy. Semin Thromb Hemost. 2016;42:513–517.
   PubMed Web of Science ®Google Scholar
• DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol. Aug 2007 ;138(3):305–315. Review
   PubMed Web of Science ®Google Scholar
• Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products (Draft). [cited 2016 September 26] Available from: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/06/WC500187409.pdf
   Google Scholar
• Schulte S. Half-life extension through albumin fusion technologies. Thromb Res. 2009;124(Suppl 2):S6–S8.
   PubMed Web of Science ®Google Scholar
• Metzner HJ, Weimer T, Kronthaler U, et al. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost. 2009;102:634–644.
   PubMed Web of Science ®Google Scholar
• Nolte MW, Nichols TC, Mueller-Cohrs J, et al. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs. J Thromb Haemost. 2012;10:1591–1599.
   PubMed Web of Science ®Google Scholar
• Osborn BL, Sekut L, Corcoran M, et al. Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur J Pharmacol. 2002;456:149–158.
   PubMed Web of Science ®Google Scholar
• Osborn BL, Olsen HS, Nardelli B, et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther. 2002;303:540–548.
   PubMed Web of Science ®Google Scholar
• Wang W, Ou Y, Shi Y. AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharm Res. 2004;21:2105–2111.
   PubMed Web of Science ®Google Scholar
• Duttaroy A, Kanakaraj P, Osborn BL, et al. Development of a long-acting insulin analog using albumin fusion technology. Diabetes. 2005;54:251–258.
   PubMed Web of Science ®Google Scholar
• Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:4810–4817.
   PubMed Web of Science ®Google Scholar
• Weimer T, Wormsbächer W, Kronthaler U, et al. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost. 2008;99:659–667.
   PubMed Web of Science ®Google Scholar
• White GC 2nd, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost. 1997;78:261–265. Review.
   PubMed Web of Science ®Google Scholar
• Kurachi K, Davie EW. Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci USA. 1982;79:6461–6464.
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535–544.
   PubMed Web of Science ®Google Scholar
• Gringeri A, Lundin B, von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 2011;9:700–710.
   PubMed Web of Science ®Google Scholar
• Collins PW, Björkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010;8:269–275.
   PubMed Web of Science ®Google Scholar
• Den Uijl IE, Fischer K, Van Der Bom JG, et al. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia. 2011;17:41–44.
   PubMed Web of Science ®Google Scholar
• Den Uijl IE, Mauser Bunschoten EP, Roosendaal G, et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand?. Haemophilia. 2011;17:849–853.
   PubMed Web of Science ®Google Scholar
• Miller GJ, Howarth DJ, Attfield JC, et al. Haemostatic factors in human peripheral afferent lymph. Thromb Haemost. 2000;83:427–432.
   PubMed Web of Science ®Google Scholar
• Björkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet. 2001;40:815–832. Review.
   PubMed Web of Science ®Google Scholar
• Stern DM, Drillings M, Nossel HL, et al. Binding of factors IX and IXa to cultured vascular endothelial cells. Proc Natl Acad Sci USA. 1983;80:4119–4123.
   PubMed Web of Science ®Google Scholar
• Heimark RL, Schwartz SM. Binding of coagulation factors IX and X to the endothelial cell surface. Biochem Biophys Res Commun. 1983;111:723–731.
   PubMed Web of Science ®Google Scholar
• Herzog E, Harris S, Henson C, et al. Biodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in rats. Thromb Res. 2014;133:900–907.
   PubMed Web of Science ®Google Scholar
• Chaudhury C, Mehnaz S, Robinson JM, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med. 2003;197:315–322.
   PubMed Web of Science ®Google Scholar
• Anderson CL, Chaudhury C, Kim J, et al. Perspective–FcRn transports albumin: relevance to immunology and medicine. Trends Immunol. 2006;27:343–348.
   PubMed Web of Science ®Google Scholar
• Kim J, Bronson CL, Hayton WL, et al. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol. 2006;290:G352–G360.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 20 2012;120:2405–2411.
   PubMed Web of Science ®Google Scholar
• Martinowitz U, Lubetsky A. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B. Thromb Res. 2013;131(Suppl 2):S11–S14.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Martinowitz U, Lissitchkov T, et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016;127:1761–1769.
   PubMed Web of Science ®Google Scholar
• Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369:2313–2323.
   PubMed Web of Science ®Google Scholar
• Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood. 2011;118:2695–2701.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Pezeshkpoor B, Pavlova A. Historical review on genetic analysis in hemophilia A. Semin Thromb Hemost. 2014 Nov;40(8):895–902.
   PubMed Web of Science ®Google Scholar
• Belvini D, Salviato R, Radossi P, et al. Molecular genotyping of the Italian cohort of patients with hemophilia B. Haematologica. 2005;90:635–642.
   PubMed Web of Science ®Google Scholar
• Morfini M, Dragani A, Paladino E, et al. Correlation between FIX genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study. Haemophilia. 2016Mar;14. [Epub ahead of print] 10.1111/hae.12916.
   Google Scholar
• Soucie JM, De Staercke C, Monahan PE, et al. Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening. Transfusion. 2013;53:1217–1225.
   PubMed Web of Science ®Google Scholar
• Sharp CP, Lail A, Donfield S, et al. High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies. J Infect Dis. 2009;200:1119–1125.
   PubMed Web of Science ®Google Scholar
• Modrow S, Wenzel JJ, Schimanski S, et al. Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates. Vox Sang. 2011;100:351–358.
   PubMed Web of Science ®Google Scholar
• Bon A, Morfini M, Dini A, et al. Desensitization and immune tolerance induction in children with severe factor IX deficiency; inhibitors and adverse reactions to replacement therapy: a case-report and literature review. Ital J Pediatr. 2015;41:12.
   PubMed Web of Science ®Google Scholar
• Ozelo MC. Surgery in patients with hemophilia: is thromboprophylaxis mandatory? Thromb Res. 2012;130(Suppl 1):S23–S26.
   Google Scholar
• Ueno M, Horikoshi I, Takahashi K, et al. Studies on oral administration of concentrated factor IX preparation. Yakugaku Zasshi. 1982;102:202–206.
   PubMed Web of Science ®Google Scholar
• Sakuragawa N, Takahashi K, Horikoshi I, et al. Basic studies on oral and rectal administration of factor IX concentrate preparation. Nihon Ketsueki Gakkai Zasshi. 1983;46:190–196.
   PubMedGoogle Scholar
• Verma D, Moghimi B, LoDuca PA, et al. Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. Proc Natl Acad Sci USA. 2010;107:7101–7106.
   PubMed Web of Science ®Google Scholar
• Gerrard AJ, Austen DE, Brownlee GG. Subcutaneous injection of factor IX for the treatment of haemophilia B. Br J Haematol. 1992;81:610–613.
   PubMed Web of Science ®Google Scholar
• Liles D, Landen CN, Monroe DM, et al. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B. Haemophilia. 1997;3:231.
   PubMedGoogle Scholar
• Miekka SI, Jameson T, Singh M, et al. Novel delivery systems for coagulation proteins. Haemophilia. 1998;4:436–442.
   PubMed Web of Science ®Google Scholar
• Russell KE, Olsen EH, Raymer RA, et al. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs. Blood. 2003;102:4393–4398.
   PubMed Web of Science ®Google Scholar
• Brooks AR, Sim D, Gritzan U, et al. Glycoengineered factor IX variants with improved pharmacokinetics and subcutaneous efficacy. J Thromb Haemost. 2013;11:1699–1706.
   PubMed Web of Science ®Google Scholar
• Kim J, Hayton WL, Robinson JM, et al. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol. 2007;122:146–155.
   PubMed Web of Science ®Google Scholar
• Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/factor IX scientific and standardization committee of the international society on thrombosis and haemostasis. Thromb Haemost. 1991;66:384–386.
   PubMed Web of Science ®Google Scholar
• Lee M, Morfini M, Schulman S, et al.; and the Factor VIII/Factor IX Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Posted in ISTH Website. 2001 Mar 21. Available from: www.isth.org/resource/group/d4a6f49a-f4ec-450f-9e0f-7be9f0c2ab2e/official_communications/fviiipharmaco.pdf?hhSearchTerms=%22morfini%22
   Google Scholar
• Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood. 2012;119:666–672.
   PubMed Web of Science ®Google Scholar
• Collins P, Chalmers E, Chowdary P, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia. 2016 Jul;22(4):487–498.
   PubMed Web of Science ®Google Scholar